Broad capabilities, established expertise


As one of the world’s most renowned companies for contract development and manufacturing, we are recognized for our reliable, high-quality service, our global capacity, our innovative technology platforms, and our extensive experience. In 2019 we provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules as well as supporting the launch of pioneering autologous cell therapies.

 

Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.


Our offerings


As the world’s largest company for contract development and manufacturing, our Pharma Biotech & Nutrition segment is recognized for its reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and extensive experience.

small molecules

We are an industry-leading integrated development and manufacturing service provider for small molecule drug substances and their intermediates.

Chemistry is core to Lonza. Our track record in producing API and intermediates extends back to the genesis of contract development and manufacturing. Thousands of compounds have been successfully developed and progressed by our R&D, process development and manufacturing teams. Many of these molecules have been scaled under accelerated timelines to meet program objectives.

biologics

In our extensive contract development and manufacturing services portfolio we use advanced technologies to quickly and efficiently deliver products such as monoclonal antibodies, complex proteins and recombinant proteins.

The field of cell and gene therapy is transforming the way patients diagnosed with cancers or genetic diseases can be treated. These novel drug candidates provide drastically improved patient outcomes and, in some cases, can be curative. However, manufacturing of such medicines pose complex new challenges. Today, the cost of production still represents a major hurdle for clinical translation and commercialization of these potentially groundbreaking therapies. New technologies are needed to enable robust and cost-efficient manufacturing of high-quality medicines. While the therapeutic opportunities for patients are exciting, the stakes for patients and drug developers are high.

We provide life science researchers with the tools they need to develop and test therapeutics, from basic research to final product release. Our Bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software for biomanufacturing.

capsules

Capsule Delivery Solutions

We design, develop and manufacture a wide range of innovative dosage forms for the biopharmaceutical industry, and the Capsugel® breadth of products is no exception. Our unique combination of science, engineering, formulation and encapsulation expertise enables our customers to optimize the bioavailability, delivery and overall performance of their products. We partner with customers globally to create novel, high-quality and customized solutions that evolve with patients’ and consumers’ taste.

We believe that the best outcome – for you and for your patients – can only come as a result of a successful collaboration. Together, we can solve the next challenge and bring your next medicine to life.

In the news


We have a broad view on the industry, and a depth of experience in developing and manufacturing therapies. Our scientific teams focus on devising credible, game-changing solutions that create value for our customers today by delivering the medicines of tomorrow.

View press releases

Our global footprint


With 37 sites across three continents and 11,148 employees, we capitalize on our global footprint and have the flexibility to address regional and even local marketplace needs.

View our locations